Gerrit  Dispersyn net worth and biography

Gerrit Dispersyn Biography and Net Worth

Dr. Gerrit Dispersyn joined Phio Pharmaceuticals Corp. in April 2017. Dr. Dispersyn is an accomplished leader in clinical, product and business development. He most recently served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporation. In this role, Gerrit was responsible for Integra’s global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integra’s Senior Management Leadership team, and several of the company’s core teams for M&A projects. Dr. Dispersyn has also been involved in Integra’s research and business activities related to Human Cells, Tissues, and Cellular and Tissue based Products (HCT/Ps), an experience that could be beneficial for Phio's newly added focus on immuno-oncology and cell therapy. Prior to that role, he was the Vice President, Product Development & Portfolio Management for Barrier Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. The company was a spin-out of Johnson & Johnson, and currently part of GlaxoSmithKline. There he led planning and implementation of all aspects of R&D operations and strategy; scientific, competitive and business intelligence; and alliance management. Dr. Dispersyn is the founder of Ingress, LLC, a consultancy company providing R&D and clinical operations support to start-up companies, supporting several pharmaceutical drug development programs. Dr. Dispersyn holds a Dr. Med. Sc. (Ph.D. in Medical Sciences), from the Faculty of Medicine, Maastricht University, Maastricht, the Netherlands, a post-graduate degree in Biomedical Imaging, and a M.Sc. in Biochemistry, both from the University of Antwerp, Belgium.

What is Gerrit Dispersyn's net worth?

The estimated net worth of Gerrit Dispersyn is at least $4.73 thousand as of June 23rd, 2017. Dr. Dispersyn owns 3,500 shares of Phio Pharmaceuticals stock worth more than $4,725 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Dispersyn may own. Learn More about Gerrit Dispersyn's net worth.

How do I contact Gerrit Dispersyn?

The corporate mailing address for Dr. Dispersyn and other Phio Pharmaceuticals executives is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. Phio Pharmaceuticals can also be reached via phone at (508) 767-3861 and via email at [email protected]. Learn More on Gerrit Dispersyn's contact information.

Has Gerrit Dispersyn been buying or selling shares of Phio Pharmaceuticals?

Gerrit Dispersyn has not been actively trading shares of Phio Pharmaceuticals in the last ninety days. Most recently, on Monday, August 16th, Gerrit Dispersyn bought 666 shares of Phio Pharmaceuticals stock. The stock was acquired at an average cost of $14.67 per share, with a total value of $9,770.22. Learn More on Gerrit Dispersyn's trading history.

Are insiders buying or selling shares of Phio Pharmaceuticals?

During the last year, Phio Pharmaceuticals insiders bought shares 7 times. They purchased a total of 20,200 shares worth more than $34,511.00. The most recent insider tranaction occured on November, 21st when CEO Robert J Bitterman bought 5,000 shares worth more than $5,700.00. Insiders at Phio Pharmaceuticals own 0.9% of the company. Learn More about insider trades at Phio Pharmaceuticals.

Information on this page was last updated on 11/21/2025.

Gerrit Dispersyn Insider Trading History at Phio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2021Buy666$14.67$9,770.22View SEC Filing Icon  
3/3/2021Buy277$27.27$7,553.79View SEC Filing Icon  
8/19/2020Buy222$22.50$4,995.00View SEC Filing Icon  
See Full Table

Gerrit Dispersyn Buying and Selling Activity at Phio Pharmaceuticals

This chart shows Gerrit Dispersyn's buying and selling at Phio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Phio Pharmaceuticals Company Overview

Phio Pharmaceuticals logo
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Read More

Today's Range

Now: $1.35
Low: $1.26
High: $1.37

50 Day Range

MA: $1.82
Low: $1.12
High: $2.48

2 Week Range

Now: $1.35
Low: $0.97
High: $9.79

Volume

377,574 shs

Average Volume

564,433 shs

Market Capitalization

$14.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92